Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:


Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Litigation Details for ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company (E.D. Tex. 2015)

See Plans and Pricing

« Back to Dashboard

ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company (E.D. Tex. 2015)

Docket   Start Trial Date Filed 2015-07-01
Court District Court, E.D. Texas Date Terminated 2017-08-25
Cause 15:1126 Patent Infringement Assigned To William C. Bryson
Jury Demand Both Referred To
Patents 5,859,006; 6,455,557; 6,469,012; 6,699,885; 9,393,238; RE38,115
Attorneys Adam K Mortara; Ahmed Jamal Davis; Alex L. Groden; Anthony H. Son; Benjamin J Whiting; Cherylyn Esoy Mizzo; David Folsom; Felicia J Boyd; J Scott McBride; Jeff M Barron; John M Hughes; John R Lane; John Wesley Samples; Jon Bentley Hyland; Melissa Richards Smith; Nosson Knobloch; Ruffin B Cordell; Sarah Marianne Cork; Todd G Vare; Victor D Vital
Firms Barnes & Thornburg LLP - Dallas; Barnes & Thornburg LLP Minneapolis; Bartlit Beck Chicago; Bartlit Beck Herman Palenchar & Scott LLP - Chicago; Bartlit Beck LLP Denver; Bartlit, Beck, Herman, Palenchar & Scott, LLP-Denver; Fish & Richardson PC - Washington DC; Fish & Richardson PC-Houston; Gillam and Smith LLP; Jackson Walker LLP; John Wesley Samples Attorney at Law Arlington; Maddox Edwards, PLLC
Link to Docket External link to docket
Small Molecule Drugs cited in ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company (E.D. Tex. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-07-22 119 Motion for Partial Summary Judgment 2003”) Exhibit 36: U.S. Patent 5,859,006 to Alain Daugan (“Daugan ‘006 Patent”) 0586-0619 … APP. # Exhibit 1: U.S. Patent No. 8,791,124 (the “‘124 Patent”) …asserted claims 1 and 3 of U.S. Patent No. 8,791,124 (the “‘124 Patent”). I. STATEMENT OF THE…‘124 Patent for inhibiting PDE5.2 II. SUMMARY OF ARGUMENT A. The Patent Act Establishes…described in the patent specification”—lest the quid pro quo bargain at the heart of the Patent Act be upset External link to document
0000-00-00 129 Response in Opposition to Motion 9,393,238 issued July 19, 2016 and is assigned to Celgene. Ex. 53, App. at 1065. It claims a method… ’124 patent contributed to your conclusion that the claims of the ’124 patent lack written…potentially, thousands of patents and dozens of Lilly’s. 10 We will return to the patent at issue in Avanir…To Existing Patents, Including Lilly’s There are 27,465 United States patents with claims …numerous patents that could be dramatically impacted by Lilly’s argument. For example, U.S. Patent No. 9,393,238 External link to document
0000-00-00 130 Additional Attachments to Main Document 463756A1, # 4 Exhibit 53 - U.S. Patent 9,393,238, # 5 Exhibit 54 - Lilly Patents with Claim Term Inhibitor,…Inhibitor, # 6 Exhibit 55 - U. S. Patent 5,674,887, # 7 Exhibit 56 - U.S. Patent 6,451,807, # 8 Exhibit 57 - Sybertz…2009), # 19 Exhibit 68 - U.S. Patent 6,245,802, # 20 Exhibit 69 - U.S. Patent 6,492,371, # 21 Exhibit 70 … Sybertz (1995), # 9 Exhibit 58 - U.S. Patent 5,393,755, # 10 Exhibit 59 - EP 0579496 A1, # 11 Exhibit…Claim Construction Hearing, # 16 Exhibit 65 - U.S. Patent RE38,115 E, # 17 Exhibit 66 - Mayo Clinic List External link to document
2017-01-31 189 Response in Opposition to Motion PDE6”); Ex. 20, US Patent No. 5,859,006 at col 48, ll. 28- 29 (Lilly tadalafil patent reporting only that…use in patents, Lilly has also admitted. And 146 United States patents use “IC50” in patent claims, …why the ’124 patent refers to obtaining the tissue from a single source. Ex. 7, ’124 patent col. 7, ll…it is their patent) and actually (UroPep has cited it before) on notice of what this patent says on the….9 As to assay conditions, like the ’124 patent the ’807 patent provides a set of conditions for the External link to document
2017-02-07 198 Motion in Limine 0001-5 2. Pfizer U.S. Patent No. 6,469,012 …Parte Reexamination Certificate for U.S. Patent No. 6,469,012 0053-87 4. Ex Parte…the ‘124 Patent”) nor prior art to the ‘124 Patent in an attempt to bolster the ‘124 Patent’s disclosure…compare the ‘124 Patent to Lilly’s U.S. Patent No. 6,451,807 (“the ‘807 Patent”) in both its present…Meaning, or Scope of the ‘124 Patent Drawn from Unrelated Patents. ........................ External link to document
0000-00-00 38 Response in Opposition to Motion at 1 (D.N.J. Oct. 11, 2007) (citing U.S. Patent No. 6,455,557). The district court in that case construed…Lilly and Brookshire infringe U.S. Patent No. 8,791,124 (“the ʼ124 Patent”) through the sale of Cialis® for…Direct Infringement of the ’124 Patent. Claim 1 of the ’124 Patent recites, in pertinent part, “… Brookshire for Direct Infringement of the ’124 Patent. .........................................7  …Brookshire for Indirect Infringement of the ’124 Patent. ....................................11  IV.  External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.